Literature DB >> 10658905

Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases.

T Moriya1, K Sakamoto, H Sasano, M Kawanaka, H Sonoo, T Manabe, J Ito.   

Abstract

We examined Ki-67, p53, p21, and p27 immunolocalization in 43 cases of apocrine lesions of the breast and correlated these findings with histologic parameters to understand their biologic significance. Twenty cases were benign, 1 case was borderline, and 22 cases were diagnosed as malignant, including 9 intraductal and 13 invasive apocrine carcinomas. Both the ratio of Ki-67-positive cases (17 of 21 [88.9%] versus 1 of 19 [5.3%]; P < .001) and the Ki-67 labeling index of positive cases examined (15.0% versus 2.7%; P < .005) were significantly higher in malignant than in benign apocrine lesions. None of the benign or borderline cases was immunohistochemically positive for p53, but 15 of 22 malignant cases (68.2%) demonstrated p53 (P < .001). In addition, the ratio of p53-positive cases was significantly higher in high nuclear grade cases (11 of 13 [84.6%]) than in intermediate nuclear grade cases (4 of 9 [44.4%]; P < .05). P53 immunoreactivity was also positively correlated with the nuclear grade of carcinoma cases examined in this study. Neither p21 nor p27 demonstrated any correlation with histologic parameters or findings of the apocrine lesions. Results of these studies suggest that Ki-67 and p53 may be good markers for differentiation between benign and malignant breast apocrine lesions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10658905     DOI: 10.1038/modpathol.3880004

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  13 in total

1.  Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.

Authors:  Naoki Kanomata; Rin Yamaguchi; Junichi Kurebayashi; Takuya Moriya
Journal:  Med Mol Morphol       Date:  2019-05-28       Impact factor: 2.309

Review 2.  [Diagnostics of benign ductal epithelial cell proliferation of the breast in biopsy material].

Authors:  H-P Sinn; C Flechtenmacher; S Aulmann
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

Review 3.  The enigmatic nature of apocrine breast lesions.

Authors:  P Zagorianakou; N Zagorianakou; D Stefanou; G Makrydimas; N J Agnantis
Journal:  Virchows Arch       Date:  2006-03-29       Impact factor: 4.064

4.  Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast.

Authors:  C Jones; S Damiani; D Wells; R Chaggar; S R Lakhani; V Eusebi
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

5.  Cystic apocrine ductal carcinoma in situ with increased EGFR expression, trisomy 7, and associated focal invasion.

Authors:  Shogo Tajima; Michihiko Waki; Hatsuko Nasu; Yoshimi Ide
Journal:  Med Mol Morphol       Date:  2014-11-06       Impact factor: 2.309

6.  A deep learning model for breast ductal carcinoma in situ classification in whole slide images.

Authors:  Fahdi Kanavati; Shin Ichihara; Masayuki Tsuneki
Journal:  Virchows Arch       Date:  2022-01-25       Impact factor: 4.064

Review 7.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

8.  Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Authors:  Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezón; Pavel Gromov; Tao Shen; Vera Timmermans; Fritz Rank
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

9.  [Atypical ductal hyperplasia and atypical epithelial proliferation of ductal type].

Authors:  W Böcker; D Hungermann; S Weigel; K Roterberg; T Decker
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

Review 10.  The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.

Authors:  R Chiarle; M Pagano; G Inghirami
Journal:  Breast Cancer Res       Date:  2000-12-20       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.